Evidence map›Paper›PMID 39052984›Full record

Trial reportClinical and translational science2024

Safety, pharmacokinetics, and food effect of sudapyridine (WX-081), a novel anti-tuberculosis candidate in healthy Chinese subjects.

Chengyin Yu, Hongjie Qian, Qingqing Wu, Yang Zou, Qicheng Ding, Yuting Cai, Liyu Liang, Juncai Xu, Lei Li, Bin Zan and 2 more

Abstract readRandomized Controlled TrialClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Population pharmacokinetic and exposure-response study of a novel anti-tuberculosis drug to inform its dosage design in phase III clinical trial.European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences · 2025
    Trial
  2. Trial
  3. New drugs for the management of tuberculosis.Current opinion in infectious diseases · 2025
    Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Chengyin YuShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0001-8665-0140
Hongjie QianCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0002-5209-805X
Qingqing WuCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-4105-290X
Yang ZouCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0003-0887-7096
Qicheng DingCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-6496-9521
Yuting CaiCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.
Liyu LiangShanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.ORCID 0000-0002-2478-9152
Juncai XuShanghai Jiatan Pharmaceutical Technology Co., Ltd, a subsidiary of Guangzhou JOYO Pharma, Shanghai, China.
Lei LiShanghai Jiatan Pharmaceutical Technology Co., Ltd, a subsidiary of Guangzhou JOYO Pharma, Shanghai, China.
Bin ZanShanghai Jiatan Pharmaceutical Technology Co., Ltd, a subsidiary of Guangzhou JOYO Pharma, Shanghai, China.
Yongguo LiShanghai Jiatan Pharmaceutical Technology Co., Ltd, a subsidiary of Guangzhou JOYO Pharma, Shanghai, China.
Yun LiuCentral Laboratory, Shanghai Xuhui Central Hospital/Zhongshan-Xuhui Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-9214-413X

Funding

Shanghai Jiatan Pharmaceutical Technology Co., Ltd.
6 · The paper itself

Abstract

This study aimed to assess the safety, pharmacokinetics, and food impact on sudapyridine (WX-081), a novel drug designed to inhibit mycobacterium ATP synthase, with clinical applications for drug-resistant tuberculosis (TB) treatment. The research comprised two arms: a single ascending dose (SAD) arm (30 to 600 mg, N = 52) and a multiple ascending dose (MAD) arm (200 to 400 mg, N = 30). The influence of food was evaluated using a 400 mg dose within an SAD cohort. Plasma concentrations of WX-081 and M3 (main metabolite of WX-081) were analyzed using a validated liquid-chromatography tandem mass spectrometry method. In the SAD arm, mean residence time (MRT

Indexed as

Antitubercular AgentsFood-Drug InteractionsHealthy VolunteersAdultArea Under CurveChinaCross-Over StudiesDose-Response Relationship, DrugEast Asian PeopleFemaleHalf-LifeHumansMaleMiddle AgedYoung AdultAntitubercular Agents

Identifiers

PMID39052984
PMCPMC10828974

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.